26295-56-7

Basic information

• Product Name: N-trifluoroacetyladriamycin
• Synonyms: N-trifluoroacetyladriamycin;(8S,10S)-7,8,9,10-Tetrahydro-8-(hydroxyacetyl)-1-methoxy-10-[[3-(trifluoroacetylamino)-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-6,8,11-trihydroxy-5,12-naphthacenedione;AD-41;N-Trifluoroacetyldoxorubicin;(1S,3S)- α-2,3,6-trideoxy-3-(2,2,2-trifluoroacetaMido)-3-glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-Methoxy-6,11-dioxo-1-naphthacenyl L-lyxo-Hexopyranoside;(8S-cis)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-Methoxy-10-[[2,3,6-trideoxy-3-[(trifluoroacetyl)aMino]-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione;NSC 283464
• CAS NO: 26295-56-7
• Molecular Formula: C₂₉H₂₈F₃NO₁₂
• Molecular Weight: 639.529
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 26295-56-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 855.4°C at 760 mmHg
• Flash Point: 471.1°C
• Appearance: /
• Density: 1.66g/cm³
• Vapor Pressure: 3.7E-31mmHg at 25°C
• Refractive Index: 1.656
• Solubility: DMSO, Methanol
• PKA: 7.35±0.60(Predicted)
• CAS DataBase Reference: N-trifluoroacetyladriamycin(CAS DataBase Reference)
• NIST Chemistry Reference: N-trifluoroacetyladriamycin(26295-56-7)
• EPA Substance Registry System: N-trifluoroacetyladriamycin(26295-56-7)

Safety Data

• Hazardous Substances Data: 26295-56-7(Hazardous Substances Data)

Usage

Chemical Properties

Red Solid

Uses

Doxorubicin (D558000) metabolite. Cytotoxic interaction with DNA.

Safety Profile

Mutation data reported. Whenheated to decomposition it emits toxic vapors of NOx andFí.

InChI:InChI=1/C29H28F3NO12/c1-10-22(36)13(33-27(41)29(30,31)32)6-17(44-10)45-15-8-28(42,16(35)9-34)7-12-19(15)26(40)21-20(24(12)38)23(37)11-4-3-5-14(43-2)18(11)25(21)39/h3-5,10,13,15,17,22,34,36,38,40,42H,6-9H2,1-2H3,(H,33,41)/t10-,13-,15-,17-,22+,28-/m0/s1

Upstream product

• 23214-92-8 doxorubicin 
• 407-25-0 trifluoroacetic anhydride 
• 25316-40-9 doxorubicin hydrochloride 
• 383-63-1 ethyl trifluoroacetate, 
• 383-64-2 S-ethyl trifluoroacetate 

Downstream Products

• 56124-62-0 valrubicin 
• 135672-45-6 N-(trifluoroacetyl) doxorubicin 14-O-(4'-aminomethyl) benzoate 
• 77331-70-5 14-O-(p-anisyldiphenylmethyl)-N-(trifluoroacetyl)doxorubicin 
• 135672-69-4 N-(trifluoroacetyl) doxorubicin 14-O-<11'-(N-(p-anisyldiphenylmethyl) amino)> undecanoate 
• 135672-70-7 N-(trifluoroacetyl) doxorubicin 14-O-<4'-(N-(p-anisyldiphenylmethyl) aminomethyl)> benzoate 
• 135672-68-3 N-(trifluoroacetyl) doxorubicin 14-O-<6'-(N-(p-anisyldiphenylmethyl) amino)> hexanoate 
• 135672-67-2 N-(trifluoroacetyl) doxorubicin 14-O-<3'-(N-(p-anisyldiphenylmethyl) amino)> propanoate 
• 77331-71-6 14-O-(p-anisyldiphenylmethyl)-5-iminodoxorubicin 

Relevant articles and documents

Unexpected transesterification of N-(trifluoroacetyl) doxorubicin with acetylsalicylic acid: Formation of 4'-O-acetyl-N-(trifluoroacetyl) doxorubicin

Three new N-(trifluoroacetyl) doxorubicin analogues have been synthesized under mild reaction conditions. An unexpected transesterification reaction was observed when N-(trifluoroacetyl) doxorubicin was treated with acetylsalicylic acid under the same con

PLATINUM-CONTAINING COMPOUNDS, AND RELATED COMPOSITIONS AND USES THEREOF

Platinum-containing compounds are generally described. Inventive compositions and uses thereof are also described.

Synthesis of new N-(trifluoroacetyl) doxorubicin analogues

Four new 14-O-acyl derivatives of N-(trifluoroacetyl) doxorubicin possessing a terminal primary amino group have been synthesized in a two steps process under mild reaction conditions.